Phase 3 N=78 Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
Chemotherapy-induced Neutropenia
Primary: Duration of Severe Neutropenia in Cycle 1 — 0.9; 1.6; 1.1; 0.9 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=19 A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
Graft vs Host Disease
Primary: Overall Response Rate (ORR) — 84.2 Percentage of participants
Phase 3 N=179 Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment — 1.27; 1.48 seconds — p==0.0345
Phase 3 N=255 Efficacy and Safety of MOX/ALB Co-administration
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) of Moxidectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura — 15.3; 13.4 percentage of participants (%)
Phase 3 N=399 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Congenital Cytomegalovirus Infection · Maternal Cytomegalovirus Infection
Primary: Number of Participants With the Composite Primary Outcome — 46; 37 Participants — p=0.42
Phase 3 N=1,831 A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
Hot Flashes
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 391; 415; 389; 106 participants
Phase 3 N=21 Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Participants With a Platelet Response — 12; 0 Participants
Phase 3 N=207 Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Acinetobacter Baumannii-calcoaceticus Complex · Hospital-acquired Bacterial Pneumonia · Ventilator-associated Bacterial Pneumonia
Primary: Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population — 12; 20 Participants
Phase 3 N=101 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Chronic Myelogenous Leukemia · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia
Primary: Percentage of Severe (Grade 3-4) Mucositis Graded According to the World Health Organization (WHO) Grading Scale — 81.6; 57.4 percentage of participants — p=0.05
Phase 3 N=39 A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
Lung Diseases, Interstitial
Primary: Area Under the Plasma Concentration-time Curve at Steady State (AUCτ,ss) Based on Sampling at Steady State (at Week 2 and Week 26) — 175; 167 Hours times nanogram per…
Phase 3 N=200 Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures
Reversal of Anticoagulant Treatment
Primary: INR Response — 74; 31 Participants
Phase 3 N=666 Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
Psoriasis
Primary: The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA…
Phase 3 N=221 A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Glioblastoma
Primary: Number of Participants Who Experienced a Dose-limiting Toxicity — 0 Participants
Phase 3 N=500 High-dose Erythropoietin for Asphyxia and Encephalopathy
Neonatal Encephalopathy · Birth Asphyxia
Primary: Number of Participants With Death or Neurodevelopmental Impairment — 126; 110 Participants
Phase 3 N=443 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Acute Myeloid Leukemia (AML)
Primary: Overall Survival (OS) — 9.6; 14.7 months — p=<0.001